• NOVEMBER 16, 2021
    • 0
    THE FDA HAS OFFICIALLY REMOVED ZHEJIANG HUAHAI PHARMACEUTICAL FROM IMPORT ALERT

    THE FDA HAS OFFICIALLY REMOVED ZHEJIANG HUAHAI PHARMACEUTICAL FROM IMPORT ALERT

    THE FDA HAS OFFICIALLY REMOVED ZHEJIANG HUAHAI PHARMACEUTICAL FROM IMPORT ALERT Somerset, NJ, November 15, 2021 – Solco is pleased to announce that the FDA has lifted the ImportAlert (IA) 66-40, “Detention Without Physical Examination of Drugs From Firms Which Have Not MetDrug GMPs”, Published Date: 11/12/2021, from Zhejiang Huahai Pharmaceutical Co. Ltd., at CoastalIndustrial

    Read more
    • OCTOBER 11, 2022
    • 0
    SOLCO HEALTHCARE US, RECEIVES FDA APPROVAL FOR TADALAFIL TABLETS

    SOLCO HEALTHCARE US, RECEIVES FDA APPROVAL FOR TADALAFIL TABLETS

    August 11, 2022 SOLCO HEALTHCARE US, RECEIVES FDA APPROVAL FOR TADALAFIL TABLETS SOMERSET, NJ — Solco Healthcare announces its FDA approval and availability of Tadalafil tablets, 2.5mg, 5mg, 10mg and 20mg, which are AB-rated generics equivalent to Cialis® and Adcirca® by Eli Lily. Tadalafil 2.5mg, 5mg, 10mg and 20mg tablets are indicated for the treatment

    Read more
    • OCTOBER 11, 2022
    • 0
    SOLCO HEALTHCARE US, RECEIVES FDA APPROVAL FOR NEBIVOLOL TABLETS

    SOLCO HEALTHCARE US, RECEIVES FDA APPROVAL FOR NEBIVOLOL TABLETS

    September 1, 2022 SOLCO HEALTHCARE US, RECEIVES FDA APPROVAL FOR NEBIVOLOL TABLETS SOMERSET, NJ — Solco Healthcare is proud to announce the FDA approval on April 7, 2022 and September 2022 availability of Nebivolol tablets, 2.5mg, 5mg, 10mg and 20mg an AB-rated equivalent to Bystolic® by Allergan, Inc. Nebivolol is a beta-adrenergic blocking agent indicated

    Read more
    • MAY 23, 2019
    • 1
    SOLCO HEALTHCARE US, RECEIVES FDA APPROVAL FOR GLYCOPYRROLATE INJECTION, 0.2 mg/mL

    SOLCO HEALTHCARE US, RECEIVES FDA APPROVAL FOR GLYCOPYRROLATE INJECTION, 0.2 mg/mL

    SOLCO HEALTHCARE US, RECEIVES FDA APPROVAL FOR GLYCOPYRROLATE INJECTION, 0.2 mg/mL CRANBURY, NJ — Solco Healthcare announces its FDA approval for Glycopyrrolate Injection, 0.2mg/mL, which is an AP-rated equivalent to Robinul® by Hikma. “We are very pleased to have received FDA approval for Glycopyrrolate injection.  This approval represents a new chapter for Solco, as we enter

    Read more

Photostream